12Mar 2022
Cardiorenal outcomes with ertugliflozin by baseline glucose‐lowering agent: An analysis from VERTIS CV

Cardiorenal outcomes with ertugliflozin by baseline glucose‐lowering agent: An analysis from VERTIS CV

The study assesses selected cardiorenal outcomes with ertugliflozin using a baseline glucose‐lowering agent. VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin vs placebo, conducted in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). In VERTIS CV, the effects of ertugliflozin on cardiorenal outcomes were consistent across subgroups of patients stratified by baseline glucose‐lowering agent.

  • #endo-diabetology

Like

Save

Share